POP Pharma
ActiveFrom the official registers: KBO 15 annual accounts at the National Bank publications in the Belgian Official Gazette
Summary
POP Pharma has been active since 2010 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €962,646 and a net result of €269,974. Equity is growing by about 12% per year across the filed financial years. Its solvency ranks better than 91% of 22,679 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).
History
Acts, filings and financial milestones
14-12
Gazette deed
Resignations: POPPE Geert (director) and DE DOBBELEER Kristien (director)Reappointments: POPPE Geert (director) and DE DOBBELEER Kristien (director) · Registered office clause · Amendment of the articles14 facts ▸
- Director resignation, POPPE Geert (director)
- Director resignation, DE DOBBELEER Kristien (director)
- Director reappointment, POPPE Geert (director (not named in the articles))
- Director reappointment, DE DOBBELEER Kristien (director (not named in the articles))
- Other provision, “uitoefening mandaat, Kwijting ontslagnemende bestuurders” (deed in Dutch)
- Registered office clause, “1741 Wambeek,Weverstraat 1” (deed in Dutch)
- General meeting, 01-12-2023
- Other provision, “BE0831.101.641, identificatie en voorgeschiedenis” (deed in Dutch)
- Amendment of the articles (3 times)
- Capital conversion, “statutair onbeschikbare eigen vermogensrekening” (deed in Dutch)
- Other provision, “vormen en meerderheden van statutenwijziging, opheffing statutair onbeschikbare eigen vermogensrekening” (deed in Dutch)
- Other provision, “uitkering uit winst lopende boekjaar of winst voorgaande boekjaar zolang jaarrekening nog niet goedgekeurd, interimdividend” (deed in Dutch)
- +2 further facts in this act
Sources:Publications in the Belgian Official GazetteFilings with the National Bank